Graves' disease is an autoimmune disorder that results into overproduction of thyroid hormones.
Thyrotoxicosis signs and symptoms include hyperactivity, irritability, insomnia, dysphoria, sweating, heat intolerance, palpitations, weakness, fatigue, weight loss despite increased appetite, diarrhea, steatorrhea polyuria, decreased libido, tachycardia, tremor, goiter, alopecia, gynecomastia, eyelid lag or retraction and rarely periodic paralysis.
Clinical features in thyrotoxic patient that suggests Graves's disease are ophthalmopathy, thyroid dermopathy, thyroid acropachy, diffuse goiter, antibodies to thyroid peroxidase or thyroglobulin and thyroid radionuclide scan demonstrating a diffuse goiter.


Two Step Process
Confirmation of thyrotoxicosis
  • Measure undetectable TSH by immunoradiometric assay
  • Confirm w/ measurement of FT4
    • FT4 is high in thyrotoxicosis
    • If FT4 is normal, FT3 should be measured because FT3 is elevated at the beginning of most episodes of thyrotoxicosis
  • For patients w/ normal TSH & FT4 levels, no further testing for thyrotoxicosis is needed
Clinical features in thyrotoxic patient that suggest Graves’ disease:
  • Ophthalmopathy
  • Thyroid dermopathy
  • Thyroid acropachy
  • Diffuse goiter
  • Antibodies to thyroid peroxidase (TPO) or thyroglobulin are present in 80% of Graves’ patients
    • Easily measured & may be used if assays for TSH-receptor antibodies are not available
  • Thyroid radionuclide scan demonstrating a diffuse goiter may suggest Graves’ disease
    • May be indicated to distinguish Graves’ hyperthyroidism from thyrotoxicosis
  • Radioactive iodine uptake is indicated when the diagnosis is in question & distinguishes causes of thyrotoxicosis having elevated or normal uptake over the thyroid gland from those w/ near-absent uptake
    • Elevated in patients w/ Graves’ disease & the pattern is diffuse
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 20 Jul 2018
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Roshini Claire Anthony, 30 Jul 2018

Canagliflozin may provide a renoprotective effect in individuals with type 2 diabetes (T2D) and a history of cardiovascular disease (CVD), according to results from the CANVAS* Program.

Stephen Padilla, 31 Jul 2018
Patients with type 2 diabetes (T2D) treated with sulphonylureas as second-line drugs are at an increased risk of myocardial infarction (MI), all-cause mortality and severe hypoglycaemia compared with those who remained on metformin monotherapy, a recent study has found.
22 Jul 2018
There appears to be a nonlinear relationship between total oestradiol and free oestradiol and all-cause mortality among older men, according to data from the Three-City cohort study. Specifically, the association is stronger for cardiovascular disease mortality and nonexistent for cancer mortality.